GLP-1 receptor agonists such as semaglutide (marketed under brand names Ozempic, Wegovy, and Rybelsus) and the dual GIP/GLP-1 agonist tirzepatide (marketed under brand names Mounjaro and Zepbound) are FDA-approved prescription medications for specific uses in type 2 diabetes management and, in some cases, chronic weight management
A new Cleveland Clinic study found those taking GLP-1s were less likely to develop stage IV disease in several cancer types, when compared to patients taking another diabetes medication, DPP-4 inhibitors
After propensity score matching, the analytic cohort comprised 26,408 matched patients: 13,204 users and 13,204 non-users
Im sure thats kind of a a relief
BPC-157 Contraindicated in Active Cancer BPC-157 promotes angiogenesis (new blood vessel formation), which means patients with active cancer should not use it
By integrating tirzepatide with a comprehensive weight management strategy, patients can expect sustainable and life-changing results
